Camber Capital Management’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Camber Capital Management’s Portfolio MNTA Stock Details MNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-450,000	Closed	-$15M	–	40
2020 Q2	$15M	Sell	450,000 -1,550,000	-78%	-$49.4M	0.86%	26
2020 Q1	$54.4M	Sell	2,000,000 -1,250,000	-38%	-$34.8M	3.25%	14
2019 Q4	$64.1M	Sell	3,250,000 -250,000	-7%	-$4M	3.26%	16
2019 Q3	$45.4M	Hold	3,500,000	–	–	2.39%	19
2019 Q2	$43.6M	Sell	3,500,000 -500,000	-13%	-$6.64M	2.03%	21
2019 Q1	$58.1M	Hold	4,000,000	–	–	2.9%	15
2018 Q4	$44.2M	Buy	4,000,000 +1,121,110	+39%	+$15.6M	2.1%	20
2018 Q3	$75.7M	Sell	2,878,890 -176,110	-6%	-$4.76M	3.24%	11
2018 Q2	$62.5M	Buy	3,055,000 +2,919,700	+2,158%	+$62.7M	2.4%	19
2018 Q1	$2.46M	Buy	+135,300	New	+$2.26M	0.12%	31
2014 Q2	–	Sell	-400,000	Closed	-$4.66M	–	47
2014 Q1	$4.66M	Sell	400,000 -400,000	-50%	-$6.77M	0.37%	38
2013 Q4	$14.1M	Hold	800,000	–	–	1.25%	26
2013 Q3	$11.5M	Hold	800,000	–	–	1.21%	25
2013 Q2	$12M	Buy	+800,000	New	+$10.6M	1.24%	25

Other funds holding MNTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

Camber Capital Management's MNTA Position: Q3 2020 in Review

Camber Capital Management sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q3 2020, closing a stake of 450,000 shares — an estimated $15M sold.

Camber Capital Management first reported a position in MNTA in Q2 2013 and held it in 14 quarters. The position peaked at $75.7M in Q3 2018. 211 funds tracked by Wall St. Rank hold MNTA as of Q3 2020.

Camber Capital Management reported no remaining Momenta Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
Camber Capital Management sold 450,000 Momenta Pharmaceuticals, Inc. shares in Q3 2020, an estimated $15M.
Camber Capital Management first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2013 and held it in 14 quarters.
Camber Capital Management's Momenta Pharmaceuticals, Inc. position peaked at $75.7M in Q3 2018.
211 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q3 2020.

Based on Camber Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.